An unhealthy response was thought as a decrease of at least 2 points within the Korean version of the Mini-Mental State Exam (K-MMSE) within the previous 6 months (the decrease in global function was determined by the investigator or caregiver)

An unhealthy response was thought as a decrease of at least 2 points within the Korean version of the Mini-Mental State Exam (K-MMSE) within the previous 6 months (the decrease in global function was determined by the investigator or caregiver). using a follow-up Clinical Global Impression of Switch (CGIC) assessment and K-MMSE carried out after 24 weeks, and security was measured from the event of adverse events and patient RASGRP1 disposition. Results In total, 164 individuals aged 74.77.52 years (meanSD) and with 5.123.64 years of education were included. The study was completed by 70% of the individuals ( em n /em =116), with 12.2% discontinuing due to adverse events. The most frequently reported Sodium Aescinate adverse events (11%) were skin lesions, such as erythema or itching, followed by gastrointestinal problems (1.2%). Either an improvement or no decrease in CGIC scores was reported for 82% of the individuals. Conclusions The immediate switching of individuals from an oral ChEI to Sodium Aescinate the rivastigmine transdermal patch without a washout period was safe and well tolerated from the probable-AD individuals in this study. strong class=”kwd-title” Keywords: cholinesterase inhibitors, rivastigmine transdermal patch, effectiveness, security, Alzheimer’s disease Intro Cholinesterase inhibitors (ChEIs) are Sodium Aescinate widely used in medical practice for the symptomatic treatment of mild-to-moderate Alzheimer’s disease (AD) and Parkinson’s-disease dementia. ChEIs are effective in improving the cognitive and global functioning of AD individuals, and are the main pharmacological treatment in the medical management of the disease.1-3 However, the incidence of adverse events associated with oral ChEIs, and particularly those of nausea and vomiting, increases with the administered dose, which can make it hard to achieve and maintain high therapeutic doses in medical practice.4-6 The recently developed rivastigmine transdermal patch represents a next generation of acetylcholinesterase treatments, and it is now available in many countries.7 By delivering the drug through the skin, directly into the bloodstream, transdermal patches avoid first-pass effects and result in reduced rates of nausea and vomiting compared with oral ChEIs.8,9 However, the different pharmacologic characteristics of the three popular ChEIs may influence the treatment responses of individual patients. Some AD individuals do not display improvements in cognitive function and quality of life, even with long term intake of a maintenance dose of ChEIs. Consistent with these observations, earlier studies have shown that AD individuals who have an inadequate response or intolerance of one ChEI may encounter sign improvement after switching to another ChEI.10-12 The goal of this study was to elucidate the efficacy, safety, and tolerability of switching from oral ChEI treatment to the rivastigmine transdermal patch in individuals with probable AD who had experienced adverse reactions or poor responses to oral ChEI treatment. Methods Patients Patients meeting the inclusion criteria for this study were ladies or males aged 50-85 years having a analysis of dementia of the Alzheimer’s type, according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision, and probable AD, according to the criteria of the National Institute of Neurological and Communicative Disorders and Stroke and the AD and Related Disorders Association13 Eligible individuals experienced mild-to-moderate disease, which was confirmed by a score within the Korean version of the Mini-Mental State Exam (K-MMSE) of 10-26.14 Each patient underwent a comprehensive evaluation Sodium Aescinate having a neurological exam and appropriate laboratory tests.15 Individuals had to have received treatment with oral ChEIs (donepezil, galantamine, or rivastigmine capsules) for a minimum of 3 months prior to baseline, and in the investigator’s clinical judgment must have been responding poorly to or been deteriorating on their current treatment. The individuals were assigned to either a poor-response group or an adverse-events group. The poor-response group comprised individuals with a loss of at least 2 points within the K-MMSE within the previous 6 months or.